New marketing authorization for indication locally advanced SCCHN, glioblastoma and anaplastic astrocytoma in adults, esophageal cancer, locally advanced or metastatic pancreatic cancer is approved in Kazakhstan.

MISSISSAUGA, ON, Dec. 3, 2012 /PRNewswire/ – YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM) today reported that CIMYM BioSciences Inc. has sold its assets relating to nimotuzumab to InnoKeys…

Innokeys Pte Ltd attends Congress of Obstetrics and Gynecology Indonesia 2015 Bandung, Indonesia (Augus 26, 2015) – Innokeys Pte Ltd attended the…

New marketing authorization for indication locally advanced unresectable or metastatic pancreatic cancer is approved in Myanmar by the Myanmar FDA. This indication…

Prof. Dr. Dirk Strumberg, Oncologist in Marien Hospital Herne, Germany  

Medical Oncology Group of Australia

Professor Dirk Strumberg from Germany (center, in blue suit), the principal investigator of phase IIB/IIIA nimotuzumab clinical trial on pancreatic cancer, in…